कंपनी का अवलोकन
Zai Lab Limited operates as a biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of therapeutic products targeting medical conditions within oncology, immunology, neuroscience, and infectious diseases. The company functions within the Healthcare sector, specifically under the Biotechnology industry, where its focus is on creating orally administered solutions such as Zejula to address complex disease states. As of the latest available data, Zai Lab holds a market capitalization of $2.42B and employs a workforce of 1784 individuals, generating total annual revenue of $460.16M in the trailing twelve months. These valuation and revenue figures position the company as a significant mid-cap entity in the biotechnology landscape, reflecting substantial market confidence despite its current lack of profitability. The scale of its operations, supported by nearly 1800 employees, suggests an organization capable of sustaining extensive research and development pipelines required for advancing oncology and immunology treatments.
वित्तीय स्वास्थ्य
The company reported revenue of $460.16M over the trailing twelve months, yet this figure contrasts sharply with a net income loss of $-175,536,992 and an EBITDA of $-214,424,000. The substantial gap between the positive revenue and negative net income reveals a cost structure characterized by high operating expenses, likely driven by the capital-intensive nature of biotechnology research, drug development, and commercialization efforts. Free cash flow stands at $-92,507,872, indicating that the company is currently consuming cash reserves to fund its operations and growth initiatives rather than generating liquidity from its core business activities. The gross margin is recorded at 10.5%, while the operating margin is significantly lower at -54.4%, and the profit margin is -38.1%, highlighting the intense cost pressures inherent in the early-to-mid stages of product lifecycle management. On the balance sheet, the company holds $689.57M in cash against $224.26M in debt, resulting in a debt-to-equity ratio of 31.34, which suggests a leveraged position relative to equity but provides a robust liquidity buffer. The current ratio is 2.45, indicating that the company possesses more than double the current assets required to meet its short-term liabilities, thus demonstrating strong short-term liquidity and the ability to manage immediate obligations without distress. Furthermore, the Return on Equity is -22.6% and the Return on Assets is -12.2%, metrics that reveal management is currently generating negative returns on the capital invested, a typical characteristic for biotech firms focused on R&D before product approval and commercial ramp-up.
मूल्यांकन आकलन
The P/E Ratio (TTM) is listed as N/A due to the lack of net income, while the Forward P/E is -15.32, implying that the market prices future earnings expectations based on anticipated profitability improvements rather than current performance. The price-to-book ratio stands at 3.31, indicating that the market values the company at a significant premium over its net book value, likely reflecting the intangible value of its drug pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 5.25 and the EV/EBITDA of -108.20 suggest that the stock is priced based on revenue generation potential rather than current cash flow or earnings, a common practice for pre-revenue or unprofitable biotechnology assets. The 52-week high is $44.34 and the 52-week low is $15.96, meaning the current trading price sits somewhere within this wide volatility range, reflecting the speculative nature of its stock performance over the past year. The beta value is 0.86, which indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to the average large-cap equity.
Growth & Income
Zai Lab Limited has demonstrated revenue growth of 17.0% year-over-year, whereas earnings growth is N/A due to the company's continued losses. Since earnings are negative, the growth trajectory of the bottom line cannot be measured in percentage terms against revenue, implying that the company is prioritizing revenue expansion and market penetration over immediate profit generation. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute income to shareholders but instead retains all earnings to reinvest into its drug discovery and development programs. This reinvestment strategy aligns with the standard operational model for biotechnology firms, where capital is directed toward advancing clinical trials and commercializing products like Zejula rather than providing income to investors. The overall growth and income profile presents a high-growth, no-income scenario where shareholder returns are expected to materialize only upon the successful commercialization of its therapeutic portfolio.